Concentrations of apelin-13 and VEGF used were 10 ng/mL and 50 ng/mL, respectively. SU1498 was used in the concentration range of 0.25-1.5 μM, depending on the assay. Results obtained from ≥3 independent experiments (Mean±SEM). Statistical analysis was performed using one-way ANOVA followed by Tukey's post hoc test in (B, D, F-H).
Supplementary Table 1: Top 15 most upregulated and downregulated genes that were expressed differently in tumors that were resistant to bevacizumab or sorafenib treatment
The table shows gene symbol, fold change, and P-value of mRNA expression changes in tumors that are resistant or sensitive to bevacizumab or sorafenib. The top 15 upregulated and downregulated genes are shown. FC = fold change; SR = sorafenibresistant; SS = sorafenib-sensitive; BR = bevacizumab-resistant; BS = bevacizumab-sensitive. The table shows gene symbol, fold change, and P-value of mRNA expression changes in tumors that are resistant or sensitive to bevacizumab or sorafenib. The top upregulated and downregulated genes are shown. FC = fold change; SR = sorafenib-resistant; SS = sorafenib-sensitive; BR = bevacizumab-resistant; BS = bevacizumab-sensitive.
Supplementary Table 2: Top 13 most upregulated and downregulated genes that were expressed differently in stroma resistant to bevacizumab or sorafenib treatment
